Species-specific and drug-specific differences in susceptibility of candida biofilms to echinocandins: Characterization of less common bloodstream isolates

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2562-2570

  Simitsopoulou, Maria ^a   Peshkova, Pavla ^a   Tasina, Efthymia ^a   Katragkou, Aspasia ^a   Kyrpitzi, Daniela ^a   Velegraki, Aristea ^b   Walsh, Thomas J ^c   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PLANKTON; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PLANKTON; SPECIES SPECIFICITY;

EID: 84877856149     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02541-12     Document Type: Article

References (61)

1. Cauda R. 2009. Candidaemia in patients with an inserted medical device. Drugs 69(Suppl 1):33-38.
2. Rueping MJ, Vehreschild JJ, Cornely OA. 2009. Invasive candidiasis and candidemia: From current opinions to future perspectives. Expert Opin. Invest. Drugs 18:735-748.
3. Cuellar-Cruz M, Lopez-Romero E, Villagomez-Castro JC, Ruiz-Baca E. 2012. Candida species: New insights into biofilm formation. Future Microbiol. 7:755-771.
4. Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, Diaz P, Vasilakos J. 2009. Characterization of mucosal Candida albicans biofilms. PLoS One 4:e7967. doi:10.1371/journal.pone.0007967.
5. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Jr, Noverr MC. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635-3644.
6. Blankenship JR, Mitchell AP. 2006. How to build a biofilm: A fungal perspective. Curr. Opin. Microbiol. 9:588-594.
7. Chandra J, Mukherjee PK, Ghannoum MA. 2008. In vitro growth and analysis of Candida biofilms. Nat. Protoc. 3:1909-1924.
8. Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Palazzi DL, Castagnola E, Halasa N, Velegraki A, Dvorak CC, Charkabarti A, Sung L, Danziger-Isakov L, Lachenauer C, Arrieta A, Knapp K, Abzug MJ, Ziebold C, Lehrnbecher T, Klingspor L, Warris A, Leckerman K, Martling T, Walsh TJ, Benjamin DK, Jr, Zaoutis TE. 2012. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr. Infect. Dis. J. 31: 1252-1257.
9. Trofa D, Gacser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
10. Mikulska M, Bassetti M, Ratto S, Viscoli C. 2011. Invasive candidiasis in non-hematological patients. Mediterr. J. Hematol. Infect. Dis. 3:e2011007. doi:10.4084/MJHID.2011.007.
11. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, Suh SP, Ryang DW. 2002. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: Comparison of bloodstream isolates with isolates from other sources. J. Clin. Microbiol. 40:1244-1248.
12. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. 2008. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 46:1206-1213.
13. Kuhn DM, Mikherjee PK, Clark TA, Pujol C, Chandra J, Hajjeh RA, Warnock DW, Soil DR, Ghannoum MA. 2004. Candida parapsilosis characterization in an outbreak setting. Emerg. Infect. Dis. 10:1074-1081.
14. Mukherjee PK, Chandra J. 2004. Candida biofilm resistance. Drug Resist. Updat. 7:301-309.
15. Sucher AJ, Chahine EB, Balcer HE. 2009. Echinocandins: The newest class of antifungals. Ann. Pharmacother. 43:1647-1657.
16. Perlin DS. 2011. Current perspectives on echinocandin class drugs. Future Microbiol. 6:441-457.
17. Katragkou A, Chatzimoschou A, Simitsopoulou M, Dalakiouridou M, Diza-Mataftsi E, Tsantali C, Roilides E. 2008. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52:357-360.
18. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
19. Choi HW, Shin JH, Jung SI, Park KH, Cho D, Kee SJ, Shin MG, Suh SP, Ryang DW. 2007. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob. Agents Chemother. 51:1520-1523.
20. Ferreira JA, Carr JH, Starling CE, de Resende MA, Donlan RM. 2009. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53: 4377-4384.
21. Fiori B, Posteraro B, Torelli R, Tumbarello M, Perlin DS, Fadda G, Sanguinetti M. 2011. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob. Agents Chemother. 55:3031-3035.
22. Miceli MH, Bernardo SM, Lee SA. 2009. In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms. Int. J. Antimicrob. Agents 34:500-502.
23. Ku TS, Bernardo SM, Lee SA. 2011. In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms. J. Med. Microbiol. 60:1708-1710.
24. Cateau E, Berjeaud JM, Imbert C. 2011. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int. J. Antimicrob. Agents 37:380-384.
25. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. 2011. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6:e24198. doi:10.1371/journal.pone.0024198.
26. Das I, Nightingale P, Patel M, Jumaa P. 2011. Epidemiology, clinical characteristics, and outcome of candidemia: Experience in a tertiary referral center in the UK. Int. J. Infect. Dis. 15:e759-e763.
27. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. 2012. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73:45-48.
28. Velegraki A, Kambouris ME, Skiniotis G, Savala M, Mitroussia-Ziouva A, Legakis NJ. 1999. Identification of medically significant fungal genera by polymerase chain reaction followed by restriction enzyme analysis. FEMS Immunol. Med. Microbiol. 23:303-312.
29. Mannarelli BM, Kurtzman CP. 1998. Rapid identification of Candida albicans and other human pathogenic yeasts by using short oligonucleotides in a PCR. J. Clin. Microbiol. 36:1634-1641.
30. Pierce CG, Uppuluri P, Tristan AR, Wormley FL, Jr, Mowat E, Ramage G, Lopez-Ribot JL. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500.
31. Seidler M, Salvenmoser S, Muller FM. 2006. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int. J. Antimicrob. Agents 28:568-573.
32. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394.
33. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
34. Chatzimoschou A, Katragkou A, Simitsopoulou M, Antachopoulos C, Georgiadou E, Walsh TJ, Roilides E. 2011. Activities of triazoleechinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob. Agents Chemother. 55:1968-1974.
35. Tournu H, Van Dijck P. 2012. Candida biofilms and the host: Models and new concepts for eradication. Int. J. Microbiol. 2012:845352. doi:10.1155/2012/845352.
36. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. Candida biofilms: An update. Eukaryot. Cell 4:633-638.
37. Katragkou A, Simitsopoulou M, Chatzimoschou A, Georgiadou E, Walsh TJ, Roilides E. 2011. Effects of interferon-gamma and granulocyte colony-stimulating factor on antifungal activity of human polymorphonuclear neutrophils against Candida albicans grown as biofilms or planktonic cells. Cytokine 55:330-334.
38. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G, Cauda R, Sanguinetti M. 2007. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45:1843-1850.
39. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35:340-355.
40. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. 2009. Biofilms of non-Candida albicans Candida species: Quantification, structure and matrix composition. Med. Mycol. 47:681-689.
41. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
42. Hasan F, Xess I, Wang X, Jain N, Fries BC. 2009. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect. 11:753-761.
43. Estivill D, Arias A, Torres-Lana A, Carrillo-Munoz AJ, Arevalo MP. 2011. Biofilm formation by five species of Candida on three clinical materials. J. Microbiol. Methods 86:238-242.
44. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. 2011. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J. Clin. Microbiol. 49:2516-2521.
45. Jacobson MJ, Steckelberg KE, Piper KE, Steckelberg JM, Patel R. 2009. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob. Agents Chemother. 53:2638-2639.
46. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
47. Bernhardt H, Knoke M, Bernhardt J. 2011. Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation. Mycoses 54:e821-e827.
48. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, Lopez-Ribot JL. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
49. Cateau E, Rodier MH, Imbert C. 2008. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J. Antimicrob. Chemother. 62:153-155.
50. Cocuaud C, Rodier MH, Daniault G, Imbert C. 2005. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 56:507-512.
51. Song JW, Shin JH, Shint DH, Jung SI, Cho D, Kee SJ, Shin MG, Suh SP, Ryang DW. 2005. Differences in biofilm production by three genotypes of Candida parapsilosis from clinical sources. Med. Mycol. 43:657-661.
52. Lattif AA, Mukherjee PK, Chandra J, Swindell K, Lockhart SR, Diekema DJ, Pfaller MA, Ghannoum MA. 2010. Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int. J. Med. Microbiol. 300:265-270.
53. Pannanusorn S, Fernandez V, Romling U. 1 November 2012. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses. [Epub ahead of print.] doi:10.1111/myc.12014.
54. Zhang J, Silao FG, Bigol UG, Bungay AA, Nicolas MG, Heitman J, Chen YL. 2012. Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. PLoS One 7:e44192. doi:10 .1371/journal.pone. 0044192.
55. Walker LA, Gow NA, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob. Agents Chemother. 57:146-154.
56. Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, Scalise G. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50: 2719-2727.
57. Melo AS, Colombo AL, Arthington-Skaggs BA. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088.
58. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. 2007. Paradoxical effect of echinocandins across Candida species in vitro: Evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
59. Bizerra FC, Melo AS, Katchburian E, Freymuller E, Straus AH, Takahashi HK, Colombo AL. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob. Agents Chemother. 55:302-310.
60. Moriyama B, Henning SA, Penzak SR, Walsh TJ. 2012. The postantifungal and paradoxical effects of echinocandins against Candida spp. Future Microbiol. 7:565-569.
61. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. 2011. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob. Agents Chemother. 55:2641-2647.